Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806675 · ClinicalTrials.gov registry record · Phase 1
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
A Phase 1 study of Male Breast Cancer and Adult Glioblastoma, sponsored by Sanjiv Sam Gambhir.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01806675 is a Phase 1 study of Male Breast Cancer and Adult Glioblastoma that has completed, run by Sanjiv Sam Gambhir. The registered enrollment target is 25 participants, below the 35-participant average among 14 other Male Breast Cancer trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01806675, a Phase 1 study of Male Breast Cancer and Adult Glioblastoma, has completed, sponsored by Sanjiv Sam Gambhir.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.
Conditions Studied
Interventions
- DRUG 18F-fludeoxyglucose (18F-FDG)
- DRUG 18F-FPPRGD2
Study Locations (1)
California
- Stanford University, School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-03-04 |
| Est. Completion | 2019-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01806675
The ClinicalTrials.gov registry entry for NCT01806675 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 14 other Male Breast Cancer trials with a reported enrollment target (29% lower). The listed sponsor is Sanjiv Sam Gambhir, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Male Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-fludeoxyglucose (18F-FDG) is the first listed.
NCT01806675 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01806675 about?
NCT01806675 is a clinical study titled "18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy". The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiv...
What is the current status of trial NCT01806675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-03-04. Estimated completion is 2019-04.
What conditions does trial NCT01806675 study?
This clinical trial studies the following conditions: Male Breast Cancer, Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Colon Cancer.
What interventions are being tested in trial NCT01806675?
The interventions under investigation include: 18F-fludeoxyglucose (18F-FDG) (DRUG), 18F-FPPRGD2 (DRUG).
Who is sponsoring clinical trial NCT01806675?
This trial is sponsored by Sanjiv Sam Gambhir, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01806675 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Male Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 1
-
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
COMPLETED · Phase 1
-
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.